SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.410
-0.050 (-1.45%)
Sep 15, 2026, 4:00 PM EDT - Market closed
SAB Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
86
Market Cap
310.26M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% |
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
| Dec 31, 2019 | 3.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| Agenus | 132.69M |
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 65.05M |
| Q32 Bio | 53.74M |
| Zentalis Pharmaceuticals | 26.87M |
| Abeona Therapeutics | 25.52M |
| Upstream Bio | 3.16M |
SABS News
- 5 days ago - SAB Biotherapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 14 days ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - SAB Biotherapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - SAB Biotherapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - SAB Biotherapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - GlobeNewsWire
- 6 weeks ago - SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET - GlobeNewsWire
- 2 months ago - Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes - GlobeNewsWire